MNG269
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- UV_RESPONSE_DN+0.408
- INTERFERON_ALPHA_RESPONSE+0.378
- INTERFERON_GAMMA_RESPONSE+0.352
- MITOTIC_SPINDLE+0.311
- ALLOGRAFT_REJECTION+0.255
- PROTEIN_SECRETION+0.236
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.208
- IL6_JAK_STAT3_SIGNALING+0.175
- TGF_BETA_SIGNALING+0.147
- ANDROGEN_RESPONSE+0.128
Top 10 suppressed
- ANGIOGENESIS-0.363
- MYC_TARGETS_V2-0.342
- NOTCH_SIGNALING-0.309
- OXIDATIVE_PHOSPHORYLATION-0.258
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.251
- PANCREAS_BETA_CELLS-0.224
- XENOBIOTIC_METABOLISM-0.181
- MTORC1_SIGNALING-0.156
- ESTROGEN_RESPONSE_LATE-0.148
- GLYCOLYSIS-0.142
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG1196 | — | — | 0.781 |
| 2 | MNG1006 | — | — | 0.771 |
| 3 | MNG442 | — | — | 0.737 |
| 4 | MNG642 | — | — | 0.736 |
| 5 | MNG310 | — | — | 0.720 |
| 6 | MNG827 | — | — | 0.718 |
| 7 | SRR4296088 | — | cohortMD2 | 0.716 |
| 8 | TCGA-05-4427-01A-21R-1858-07 | — | cohortA1 | 0.712 |
| 9 | TCGA-D8-A1Y0-01A-11R-A14M-07 | — | A | 0.700 |
| 10 | MNG997 | — | — | 0.696 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 22 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| UV_RESPONSE_DN | 0.408 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.378 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.352 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.311 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.255 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.236 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.208 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.175 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.147 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.128 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.122 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.099 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.090 | Idelalisib | — uncovered |
| PEROXISOME | 0.081 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.062 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.060 | Inavolisib | — uncovered |
| MYOGENESIS | 0.055 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.050 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.022 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.017 | Idelalisib | — uncovered |